Physician profile
Leigha Sharp
NPI 1386091288
$5,849.89
in general payments reported to CMS, 2019-2025
23 companies · $1,987 in 2025
The $1,987 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $362 · 2021: $675 · 2022: $609 · 2023: $992 · 2024: $1,224 · 2025: $1,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,190 · Education: $13.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,190.39 |
| Education | $13.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $896.45 | 2020-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $783.57 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $691.19 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $583.70 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $511.35 | 2021-2025 | |
| Leo Pharma INC. | $411.60 | 2021-2025 | Adbry |
| Lilly USA, LLC | $310.54 | 2020-2024 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $297.82 | 2020-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $296.73 | 2020-2025 | Tremfya, Stelara, Simponi |
| Amgen INC. | $152.90 | 2020-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $140.20 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $138.69 | 2023-2025 | Zoryve |
| Incyte Corporation | $99.81 | 2023-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $99.00 | 2021 | |
| Almirall LLC | $77.50 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $73.28 | 2023-2024 | Sotyktu |
| Pfizer INC. | $70.42 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $55.45 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.25 | 2021-2025 | Cabtreo |
| Mayne Pharma Commercial LLC | $49.65 | 2020-2025 | |
| Dermira, INC. | $21.31 | 2020 | |
| Organon LLC | $18.77 | 2025 | Vtama |
| Epi Health, LLC | $18.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigha Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.